Dimensional Fund Advisors LP Has $1.21 Billion Position in Pfizer Inc. (NYSE:PFE)

Dimensional Fund Advisors LP trimmed its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 7.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,974,387 shares of the biopharmaceutical company's stock after selling 3,264,945 shares during the period. Pfizer makes up approximately 0.4% of Dimensional Fund Advisors LP's holdings, making the stock its 28th largest holding. Dimensional Fund Advisors LP owned approximately 0.74% of Pfizer worth $1,208,444,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Briaud Financial Planning Inc bought a new position in Pfizer in the third quarter worth $30,000. GoalVest Advisory LLC increased its stake in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 811 shares during the period. Mizuho Securities Co. Ltd. acquired a new position in Pfizer in the third quarter worth about $34,000. VisionPoint Advisory Group LLC boosted its holdings in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $36,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. BMO Capital Markets reiterated an "outperform" rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Morgan Stanley upped their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 2nd. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a "buy" rating and a $36.00 target price on the stock. Finally, Argus cut Pfizer from a "buy" rating to a "hold" rating in a report on Friday, March 22nd. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $36.00.

Pfizer Stock Down 0.6 %

Pfizer stock traded down $0.17 during midday trading on Friday, reaching $28.01. The stock had a trading volume of 25,849,775 shares, compared to its average volume of 46,206,912. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.05. The firm's fifty day simple moving average is $27.00 and its 200-day simple moving average is $28.10. The stock has a market capitalization of $158.72 billion, a P/E ratio of -466.76, a price-to-earnings-growth ratio of 1.19 and a beta of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same period last year, the company earned $1.23 earnings per share. The firm's revenue was down 19.5% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.00%. The ex-dividend date is Thursday, May 9th. Pfizer's dividend payout ratio (DPR) is -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.